-+ 0.00%
-+ 0.00%
-+ 0.00%

Advicenne says Sibnayal gains reimbursement approval in Spain for dRTA treatment

PUBT·07/20/2026 16:03:02
Listen to the news
Advicenne says Sibnayal gains reimbursement approval in Spain for dRTA treatment
  • Advicenne’s Sibnayal won reimbursement in Spain for distal renal tubular acidosis, ending an early access program.
  • Reimbursed prices set at EUR 409.84 for the 24 mEq pack, EUR 136.62 for the 8 mEq pack.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Advicenne SA published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.